Abstract: This invention relates to the use of substituted 1-benzyl-1H-indazole-3-carboxylic acids to interrupt pregnancy. These compounds are described in the U.S. Pat. No. 3,895,026 assigned to the same assignee of the present patent application.

Abstract: The present specification relates to the antiatherosclerotic use of khellin and related furochromones, and further provides novel antiatherogenic 6-halofurochromones.

Abstract: Multiple daily dosing with amidinoureas of the formula ##STR1## produces a significant and sustained decrease in blood pressure in humans.

Abstract: Disclosed is a creamy or milky skin cosmetic composition consisting of an oil-in-water emulsion in which an oily substance is dispersed in water with the aid of an emulsifying agent composed of at least glycyrrhizic compound selected from glycyrrhizic acid and salts thereof and at least one water-soluble polysaccharide selected from pectin, karaya gum, locust bean gum and xanthan gum. This skin cosmetic composition causes no irritation to the skin and hence has great safety for the skin, as contrasted with skin cosmetic compositions containing synthetic emulsifiers. In addition, it exhibits very excellent emulsion stability and storage stability and presents a very attractive appearance (fine texture and good gloss) owing to the synergistic effect of the aforesaid glycyrrhizic compound and water-soluble polysaccharide.

Abstract: Vasodilating octahydro-indolo[2,3-a]quinolizine derivatives of the formula ##STR1## wherein Q is hydrogen or an A--CH.sub.2 --CH.sub.2 -- group and A is cyano or --COOR, wherein R is C.sub.1-6 alkyl.

Abstract: Thyroid hormones such as thyroxine and triiodothyronine are assayed in biological fluid samples by a competitive binding analysis in which a fluorescent label is used. Upon formation of complexes, the fluorescence of the labelled compound is released, and the hormone can be assayed by measuring the fluorescence of the mixture and comparing the result with standard data. Fluorescein is the preferred label. The process can be operated in a continuous flow manner.

Abstract: A method is provided for preparing immunoassay reagents involving labeled members of specific binding pairs substantially enriched relative to contaminating labeled materials. The method involves conjugating a member of a specific binding pair to a support by a covalent bond which is cleavable under mild conditions to provide a binding pair member-support conjugate. Combining the binding pair member-support conjugate with a labeled composition containing the reciprocal member of the binding pair, so that the labeled reciprocal member becomes bound to the support through the binding of the specific binding pair. Separating the support to which is bound the labeled member from the remaining labeled material and then cleaving the bond joining the labeled specific binding pair to the support to provide labeled reagent for immunoassays.

Abstract: The present invention provides a method for the preparation of a specific immune serum by immunizing IAP in animals other than humans and absorbing the thus obtained serum with normal human serum.

Abstract: Abnormally high ratios of low density and very low density lipoproteins to high denisty lipoproteins, an etiological factor in vascular conditions, are reduced by oral or parenteral administration of acylcarnitine which increases the level of high density lipoproteins.

Abstract: The level of blood triglycerides is controlled by administration of polymers of unsaturated carboxylic acids, for example, copolymers of such acids with high molecular weight olefins or vinyl ethers.

Abstract: s-Phenenyltris(sulfonylimino)tri-benzene mono- and di-sulfonic acids and their salts which are useful as complement inhibitors.

Abstract: A method is described for preparing a human platelet analog for use as a reference control in particle analysis instrumentation of the Coulter type. Goat erythrocytes from individual goats which have been selected with respect to age, sex, selective breeding, a controlled environment, prior veterinary treatment, and diet are altered in size and/or combined with samples from several goats, as needed, to obtain a blend for use as a reference control for automated particle counting equipment in which the goat erythrocytes simulate in number, size and distribution the platelets in human whole blood. The controls are useful as a free-standing reference for determination of human platelets only, or can be added to whole blood reference controls for multi-parameter instruments.

Abstract: Amines of the formula I ##STR1## method of preparing the same and pharmaceutical compositions and method for treating cardiovascular disorders by blocking the .beta.-receptors of the heart in combination with a peripheral vasodilating activity.

Abstract: Amines of the formula I ##STR1## method of preparing the same and pharmaceutical compositions and method for treating cardiovascular disorders by blocking the .beta.-receptors of the heart in combination with a peripheral vasodilating activity.

Abstract: Immunoassays are provided employing antibodies and fluorescer-quencher (F-Q) chromophoric pair, wherein one or both of the chromophoric pair are bonded to antibodies. Depending on the particular ligand of interest, various reagent combinations can be employed, where the amount of quenching is directly related to the amount of ligand present in the assay medium.In carrying out the assay, the unknown and antibody specific for the ligand of interest to which is bound one of the F-Q pair, are combined in an aqueous buffered medium. Depending on the protocol, different assay reagents are employed in the aqueous buffered medium: (1) ligand analog bonded to the other of the F-Q pair; (2) antibodies specific for the ligand to which is bound the other of the F-Q pair or; finally, (3) a combination of a plurality of ligands bonded together through linking groups to a hub molecule, usually a polymer, in combination with antibody bound to the other of the F-Q pair.

Abstract: A method of treating re-entrant arrhythmias comprising administering an effective dose of tetra-alkyl quaternary ammonium salt is provided. Pharmaceutical formulations containing a tetra-alkyl quaternary ammonium salt as the active ingredient are disclosed.

Abstract: Antianginal pharmaceutical compositions containing as the active ingredient a compound of the formula ##STR1## wherein R.sub.1 is hydrogen, unsubstituted or hydroxyl-substituted alkyl of 1 to 4 carbon atoms; allyl; or unsubstituted or halo-, methyl-, methoxy- or trifluoromethyl-substituted benzyl; andX is oxygen or sulfur;or a non-toxic, pharmaceutically acceptable acid addition salt thereof; and methods of treating angina pectoris therewith.

Abstract: This invention relates to a diet supplement for enhancing the coat of felines and canines. More specifically, this invention relates to a formulation consisting of a primary component, capsicum tetragonum, which is mixed with kelp and a gelatinous material. The formulation is especially useful during those periods of time when the felines or canines shed their coats. The primary effect of this formulation is to enhance the growth of the coat and intensify the color thereof during the life of the feline or canine.

Abstract: Abnormally high ratios of low density and very low density lipoproteins to high density lipoproteins, an etiological factor in vascular conditions, are reduced by oral or parenteral administration of carnitine which increases the level of high density lipoproteins.

Abstract: A gelatin capsule unit dosage form containing triamterene, 2,4,7-triamino-6-phenylpteridine, which results in rapid dissolution of the active ingredient. The dosage form comprises the addition of a combination of a surfactant and a carbonate or bicarbonate salt as diluents.